Omecamtiv mecarbil
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Omecamtiv mecarbil
- Molecular weight
- 401.44
- Structure (SMILES)
- COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1
- 1 piperazinecarboxylic acid 4 2 fluoro 3 6 methyl 3 pyridinyl amino carbonyl amino phenyl methyl methyl ester
- 1-PIPERAZINECARBOXYLIC ACID, 4-((2-FLUORO-3-((((6-METHYL-3-PYRIDINYL)AMINO)CARBONYL)AMINO)PHENYL)METHYL)-, METHYL ESTER
- 25 mg omecamtiv mecarbil
- 25 mg Omecamtiv Mecarbil
- 37.5 mg Omecamtiv Mecarbil
- 50 mg Omecamtiv Mecarbil
- ck 1827452
- CK-1827452
- CK-1827452 12.5mg capsule
- CK-1827452 25mg capsule
- omecamtiv mecarbil
- Omecamtiv mecarbil
- Omecamtiv Mecarbil
- Omecamtiv Mecarbil (OM)
- omecamtiv mecarbil [INN]
- OMECAMTIV MECARBIL [USAN]
- Omecamtiv mecarbil [WHO-DD]
- omecamtiv mecarbil inn
- omecamtiv mecarbil usan
- omecamtiv mecarbil who dd
- omecamtiv mecarbilo
- Omecamtiv mecarbilo
- ATC classification codes
- C01CX10
Sources for recorded values
- CAS registry numbers
- 873697-71-3
- ChEMBL ID
- CHEMBL1800955
- InChIKey
- RFUBTTPMWSKEIW-UHFFFAOYSA-N
- PubChem compound IDs
- 11689883
- FDA ingredient codes (UNII)
- 2M19539ERK
- Status
- application_withdrawn
- Status date
- 7 May 2024
- Approved indications
- Treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction less than 30%
- Product number
- EMEA/H/C/006112
- Authorisation holder
- Cytokinetics (Ireland) Limited
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Heart Failure, Systolic
European medicines record
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- omecamtiv mecarbil
- Type
- Synthetic organic
- Drug name stem
- -tiv
- Mechanism
- Cardiac myosin activator
- Action type
- ACTIVATOR
- Target
- Cardiac myosin
- Protein identifier
- A7E2Y1
- Mechanism
- Cardiac myosin activator
- Action type
- ACTIVATOR
- Target
- Cardiac myosin
- Protein identifier
- P08590
- Mechanism
- Cardiac myosin activator
- Action type
- ACTIVATOR
- Target
- Cardiac myosin
- Protein identifier
- P10916
- Mechanism
- Cardiac myosin activator
- Action type
- ACTIVATOR
- Target
- Cardiac myosin
- Protein identifier
- P12829
- Mechanism
- Cardiac myosin activator
- Action type
- ACTIVATOR
- Target
- Cardiac myosin
- Protein identifier
- P12883
- Mechanism
- Cardiac myosin activator
- Action type
- ACTIVATOR
- Target
- Cardiac myosin
- Protein identifier
- P13533
- Mechanism
- Cardiac myosin activator
- Action type
- ACTIVATOR
- Target
- Cardiac myosin
- Protein identifier
- Q01449
Open Targets mechanisms
- Mechanism
- Cardiac myosin activator
- Action type
- ACTIVATOR
- Target
- Cardiac myosin
- Condition
- Cardiovascular Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000319
- Subject identifier
- D002318
- Condition
- Heart Failure
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003144
- Subject identifier
- D006333
- Condition identifier
- EFO_0000319
- Condition identifier
- EFO_0001425
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003144
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003913
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001207
- Condition identifier
- HP_0001297
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004995
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005252
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006993
- NCT00624442
- NCT00748579
- NCT00941681
- NCT01077167
- NCT01300013
- NCT01380223
- NCT01737866
- NCT01786512
- NCT02695420
- NCT02929329
- NCT03759392
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 2
- Polar surface area
- 86.8
- Calculated partition coefficient (ALogP)
- 3.06
- Calculated partition coefficient (XLogP)
- 1.4
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 29
- Molecular formula
- C20H24FN5O3
- Monoisotopic mass
- 401.18631781
- Natural product
- No
- Recorded assays
- 363
- Active assays
- 9
Active assay types
- Confirmatory
Solubility
- Median
- 2,200
- Mean
- 2,200
- Minimum
- 2,200
- Maximum
- 2,200
- Unit
- ug/mL
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- Solubility
Oral bioavailability
- Median
- 90
- Mean
- 90
- Minimum
- 80
- Maximum
- 100
- Unit
- %
- Assays
- 2
- Standard deviation
- 14.1421
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Plasma protein binding
- Median
- 79.6
- Mean
- 79.6
- Minimum
- 79.6
- Maximum
- 79.6
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- PPB
Related records
Trials (16)
- A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers
- A Study of CK-1827452 Infusion in Stable Heart Failure
- COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure
- Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension
- Omecamtiv Mecarbil Post-trial Access Study
- Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients
- Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults
- Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart Failure
- Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency
- PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina
- Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction
- Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction
- Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults
- Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure
- Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)
- Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
In development for (2)
- Cardiovascular disorder Phase 3
- Heart failure Phase 3
Other linked conditions (1)
- Systolic heart failure